2 completed, 1 withdrawn. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow brigimadlin: new trials by email Literature Review of brigimadlin trials Research Report on brigimadlin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma Brigimadlin, Ezabenlimab, Gemcitabine - Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS) | Phase 3 | Withdrawn | Boehringer Ingelheim | 2024-06-27 | 2024-07-17 | |
| Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma Brigimadlin - Liposarcoma, Dedifferentiated | Phase 3 | Completed | Boehringer Ingelheim | 138 | 2023-12-13 | 2026-01-09 |
| Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma Brigimadlin, Doxorubicin - Liposarcoma, Dedifferentiated | Phase 2 / Phase 3 | Completed | Boehringer Ingelheim | 400 | 2022-03-31 | 2026-03-02 |
Liposarcoma (2) · Dermatofibrosarcoma (1) · Histiocytoma, Malignant Fibrous (1)
Australia (2) · Canada (2) · Japan (2) · United Kingdom (2) · United States (2) · Argentina (1) · Belgium (1) · Brazil (1) · China (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Greece (1)
2023 (1)